Investment Thesis

. New product launches in the skin health and self-care segments, particularly innovations that align with consumer preferences, could significantly boost sales. Any strategic acquisitions or partnerships announced could enhance Kenvue's market position and growth trajectory, influencing stock performance.

Competitive Moat

is its strong brand equity, supported by a portfolio of well-established names such as Neutrogena, Tylenol, and Listerine. These intangible assets create significant switching costs as consumers develop loyalty to these trusted brands. The company also benefits from economies of scale due to its backing by Johnson & Johnson, allowing for more competitive pricing and marketing capabilities. Over the next 5-10 years, this advantage is expected to remain durable, although threats from emerging health brands and private label products could erode market share in certain segments.

Growth Engine

Future revenue growth for Kenvue is expected to derive from an expanding total addressable market (TAM) in the consumer health space, projected to grow as consumers prioritize health and wellness. The company has pricing power, particularly in its skin health and self-care segments, where innovation and brand loyalty support higher price points. While there is potential for organic growth, particularly through new product launches and geographic expansion, the company may also pursue strategic acquisitions to bolster its market position. Currently, Kenvue is gaining market share, particularly in the skin health segment, which is witnessing heightened consumer interest.